Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000598464 | SCV000707610 | uncertain significance | not provided | 2017-04-13 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000598464 | SCV001145901 | uncertain significance | not provided | 2019-06-27 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001349372 | SCV001543714 | uncertain significance | Autosomal recessive ataxia, Beauce type; Emery-Dreifuss muscular dystrophy 4, autosomal dominant | 2023-08-04 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 501297). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This sequence change replaces aspartic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 5399 of the SYNE1 protein (p.Asp5399Gly). This variant is present in population databases (rs747824937, gnomAD 0.004%). This variant has not been reported in the literature in individuals affected with SYNE1-related conditions. |
Revvity Omics, |
RCV000598464 | SCV003826350 | uncertain significance | not provided | 2022-12-08 | criteria provided, single submitter | clinical testing |